文献速递头颈部肿瘤放疗放疗物理与技术

Prexasertib联合同步放化疗治疗局部晚期头颈部鳞癌的1b期试验

A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.
PubMed 文献 · Radiother Oncol · 2021-02-09

这项1b期试验探索了CHK1抑制剂prexasertib联合顺铂-放疗(A部分)或西妥昔单抗-放疗(B部分)治疗既往未治的局部晚期头颈部鳞状细胞癌的可行性。A部分7例接受20 mg/m2 prexasertib联合顺铂-放疗,该剂量超过最大耐受剂量(MTD);B部分18例接受20-40 mg/m2 prexasertib联合西妥昔单抗-放疗,确定30 mg/m2为MTD。两联合方案常见不良事件为中性粒细胞减少、血小板减少、吞咽困难、口腔炎等,发热性中性粒细胞减少为剂量限制性毒性;A、B部分客观缓解率分别为71.4%和83.3%,但样本量小和随访有限限制疗效解读。

要点

  • Prexasertib 20 mg/m2联合顺铂-放疗超过MTD,未确定安全剂量。
  • Prexasertib联合西妥昔单抗-放疗的MTD为30 mg/m2。
  • 发热性中性粒细胞减少是两联合方案的剂量限制性毒性。

核心结论

  • 本研究未确定prexasertib联合顺铂-放疗的安全剂量,但证明prexasertib可安全联合西妥昔单抗-放疗。

研究设计与样本

  • 1b期试验,采用改良的时间-事件持续再评估方法递增prexasertib剂量。
  • A部分:7例既往未治的局部晚期HNSCC接受prexasertib联合顺铂-放疗。
  • B部分:18例既往未治的局部晚期HNSCC接受prexasertib联合西妥昔单抗-放疗。
  • 药代动力学(PK)分析采用标准非房室方法,抗肿瘤活性按RECIST 1.1评估。

主要发现

  • A部分7例接受20 mg/m2 prexasertib联合顺铂-放疗,该剂量超过MTD,未评估其他剂量。
  • B部分18例接受prexasertib 20-40 mg/m2联合西妥昔单抗-放疗,30 mg/m2确定为MTD。
  • 两联合方案最常见的治疗中出现的不良事件包括中性粒细胞减少、血小板减少、吞咽困难、口腔炎、口干、贫血、放射性皮肤损伤和恶心。
  • Prexasertib的PK与既往单药治疗数据一致。
  • A部分和B部分的总体缓解率分别为71.4%和83.3%,但样本量小和随访有限限制疗效解读。

关键数值与推荐

  • A部分:prexasertib 20 mg/m2联合顺铂-放疗超过MTD。
  • B部分:prexasertib 30 mg/m2联合西妥昔单抗-放疗为MTD。
  • 剂量限制性毒性:两联合方案均为发热性中性粒细胞减少。
  • 总体缓解率:A部分71.4%,B部分83.3%(RECIST 1.1)。

临床怎么用

  • Prexasertib联合西妥昔单抗-放疗的MTD为30 mg/m2,可作为后续研究参考。
  • Prexasertib联合顺铂-放疗未确立安全剂量,临床不宜直接采用20 mg/m2方案。
  • 两联合方案均需密切监测发热性中性粒细胞减少等血液学毒性。

局限性

  • 样本量小且随访有限,限制疗效数据的解读。
  • A部分仅评估了20 mg/m2一个剂量,未探索其他剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This study explored the feasibility of safely combining prexasertib, with cisplatin-radiotherapy (Part A) or cetuximab-radiotherapy (Part B) in patients with previously untreated, locoregionally advanced head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: Escalating doses of prexasertib were administered in each combination using a modified Time-to-Event Continual Reassessment Method. Pharmacokinetic (PK) analysis was performed using standard non-compartmental methods of analysis. Antitumor activity was evaluated using RECIST version 1.1. RESULTS: In Part A, 7 patients received 20 mg/m2 prexasertib and cisplatin-radiotherapy. This dose exceeded the maximum tolerated dose (MTD); no other prexasertib dose was assessed. In Part B, 18 patients received prexasertib (20-40 mg/m2) and cetuximab-radiotherapy. The 30 mg/m2 dose of prexasertib was determined as the MTD. Febrile neutropenia was the dose-limiting toxicity in each arm. Most common treatment-emergent adverse events with both combinations were neutropenia, thrombocytopenia, dysphagia, stomatitis, dry mouth, anemia, radiation skin injury [reported term radiation dermatitis], and nausea. PK of prexasertib was consistent with previously published data following prexasertib monotherapy. Overall response rate in Parts A and B was 71.4% and 83.3%, respectively. The small number of patients and follow-up limits the interpretation of efficacy data. CONCLUSION: This study did not establish a safe dose of cisplatin-radiotherapy. However, it demonstrates the proof-of-principle that prexasertib could be safely combined with cetuximab-radiotherapy. These data will provide the basis to leverage the potential radio-sensitization properties of a CHK1 inhibitor in combination with radiation or other targeted agents in a variety of therapeutic settings.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yang ES, Deutsch E, Mehmet A, et al. A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma. Radiother Oncol. 2021. PMID: 33577866. doi:10.1016/j.radonc.2021.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。